Compare PZZA & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | OABI |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.7M | 696.4M |
| IPO Year | 1995 | 2021 |
| Metric | PZZA | OABI |
|---|---|---|
| Price | $19.70 | $4.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $29.00 | $8.33 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 7.09% | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $2,068,421,000.00 | $18,666,000.00 |
| Revenue This Year | N/A | $87.73 |
| Revenue Next Year | N/A | $25.31 |
| P/E Ratio | $42.30 | ★ N/A |
| Revenue Growth | ★ 14.07 | N/A |
| 52 Week Low | $18.92 | $1.32 |
| 52 Week High | $55.74 | $5.43 |
| Indicator | PZZA | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 56.20 |
| Support Level | $19.31 | $1.71 |
| Resistance Level | $24.25 | $5.06 |
| Average True Range (ATR) | 0.62 | 0.35 |
| MACD | 0.18 | -0.05 |
| Stochastic Oscillator | 32.88 | 66.67 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.